$30.87+0.39 (+1.28%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD
Viridian Therapeutics (VRDN) Institutional Ownership
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
Sources Ownership filingsQuarter ended How we compute thisNot investment advice
5 figures withheld by our checks. Each blank figure names its reason.
13F fund flowQuarter ended Jun 30, 2026*. Withheld: many filers have already reported a later quarter, so their changes in this quarter are not on file and the counts of new, added, trimmed and closed positions are not shown. These positions are 140 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
SHARES HELD BY 13F FILERS
withheld
withheld by our checks · 219 filers, Jun 30, 2026
# 13F FUNDS
219
13F VALUE
$2.5B
136.6M shares
Not reported in the company's filings for this period.
Insider trades · latest filings (Form 4)routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Aug 19, 2026 | Tousignant Jennifer | Chief Legal Officer | Disposed · Open-market sale | 4,212 | $24.50 | ↗ |
| Aug 19, 2026 | Tousignant Jennifer | Chief Legal Officer | Acquired · Option exercise | 10,000 | $14.41 | ↗ |
| Aug 19, 2026 | Tousignant Jennifer | Chief Legal Officer | Disposed · Open-market sale | 10,000 | $24.50 | ↗ |
| Aug 19, 2026 | Tousignant Jennifer | Chief Legal Officer | Disposed · Option exercise | 10,000Stock Option (Right to Buy) | — | ↗ |
| Aug 14, 2026 | Tripuraneni Radhika | Chief Medical Officer | Acquired · Option exercise | 40,000 | $13.21 | ↗ |
| Aug 14, 2026 | Tripuraneni Radhika | Chief Medical Officer | Disposed · Option exercise | 40,000Stock Option (Right to Buy) | — | ↗ |
| Jul 1, 2026 | CAIN CHRISTOPHER W. | director | Acquired · Grant / award | 32,341Stock Option (Right to Buy) | — | ↗ |
| Jul 1, 2026 | Ajer Jeffrey Robert | director | Acquired · Grant / award | 32,341Stock Option (Right to Buy) | — | ↗ |
| Jul 1, 2026 | Moses Jennifer K. | director | Acquired · Grant / award | 32,341Stock Option (Right to Buy) | — | ↗ |
| Jul 1, 2026 | Gheuens Sarah | director | Acquired · Grant / award | 32,341Stock Option (Right to Buy) | — | ↗ |
| Jul 1, 2026 | Kiselak Tomas | director | Acquired · Grant / award | 32,341Stock Option (Right to Buy) | — | ↗ |
| Jul 1, 2026 | Morris Arlene | director | Acquired · Grant / award | 32,341Stock Option (Right to Buy) | — | ↗ |
| May 11, 2026 | Fairmount Funds Management LLC | director | Acquired · Open-market buy | 1,176,470 | $17.00 | ↗ |
| Mar 3, 2026 | Harmon Seth | Chief Financial Officer | Disposed · Tax withholding | 2,031 | $30.19 | ↗ |
| Mar 3, 2026 | Beetham Thomas W. | Chief Operating Officer | Disposed · Tax withholding | 3,048 | $30.19 | ↗ |
| Mar 3, 2026 | Tousignant Jennifer | Chief Legal Officer | Disposed · Tax withholding | 1,675 | $30.19 | ↗ |
| Mar 3, 2026 | Mahoney Stephen F. | President and CEO | Disposed · Tax withholding | 7,408 | $30.19 | ↗ |
| Mar 3, 2026 | Tousignant Jennifer | Chief Legal Officer | Acquired · Option exercise | 5,169 | — | ↗ |
| Mar 3, 2026 | Tousignant Jennifer | Chief Legal Officer | Disposed · Tax withholding | 1,724 | $29.32 | ↗ |
| Mar 3, 2026 | Tousignant Jennifer | Chief Legal Officer | Disposed · Option exercise | 5,169Restricted Stock Units | — | ↗ |
* Holdings as reported for Jun 30, 2026, 140 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How many 13F filers hold Viridian Therapeutics?
Viridian Therapeutics was held by 219 13F filers as of Jun 30, 2026.
Not investment advice.

